Peptide optimization to improve antigen presentation and antitumor responses in sarcoma
- 1Innovative Immunological Models Unit, National Cancer Institute IRCCS - “Fond G. Pascale” , ,
- 2Sarcoma and Rare Tumors Medical Oncology Unit, National Cancer Institute IRCCS - “Fond G. Pascale” , ,
- 3Orthopedic Oncologic Surgery, National Cancer Institute IRCCS - “Fond G. Pascale” , ,
Abstract
Sarcomas are rare and heterogeneous malignancies for which therapeutic options remain limited, particularly in advanced disease. Standard treatments, including surgery, radiotherapy, chemotherapy, and approved targeted agents, provide marginal improvements in progression-free and overall survival, highlighting the need for immunotherapeutic strategies. Therapeutic cancer vaccines represent a promising strategy, but clinical efficacy has been limited by low antigen immunogenicity and an immunosuppressive tumor microenvironment (TME). Enhancing antigen presentation and T-cell receptor (TCR) engagement through heteroclitic peptide engineering may overcome immune tolerance and improve vaccine efficacy. Preliminary data from our group demonstrate that heteroclitic peptides modified at TCR-facing and anchor residues enhance antigen-specific T-cell recognition, cross-reactivity with wild-type epitopes, and tumor control in preclinical models. In this study, we aim to design and validate optimized heteroclitic epitopes derived from sarcoma-associated TAAs. We developed an integrated computational and experimental workflow to identify and optimize HLA-A*02:01-restricted epitopes derived from sarcoma-associated TAAs. Candidate wild-type (WT) peptides were selected using NetMHCpan 4.1 based on predicted HLA binding affinity and subsequently engineered through systematic amino acid substitutions to generate heteroclitic variants. Optimized peptides were evaluated by structural modeling and molecular docking, followed by experimental in vitro validation using T2-cell HLA stabilization assays. Their immunogenicity was assessed ex vivo in peripheral blood mononuclear cells (PBMCs) isolated from HLA-A*02:01-positive sarcoma patients using IFN-γ ELISpot and peptide–HLA dextramer analyses. The sequential optimization strategy generated heteroclitic variants with markedly improved predicted HLA-A*02:01 binding for most target proteins. Structural modeling indicated preservation of the peptide backbone and TCR-accessible surface for the majority of selected variants. These predictions were supported experimentally: several heteroclitic peptides enhanced HLA-A*02:01 stabilization and prolonged peptide–MHC complex persistence in T2 cells. Ex vivo, optimized peptides induced stronger antigen-specific IFN-γ responses than their wild-type counterparts, with significant increases for SET, CAGE, PTPN1 and MAGE-A3, while multimer staining demonstrated recognition of heteroclitic peptide–HLA complexes by wild-type-primed CD8 ⁺ T cells. These findings establish a transferable workflow for engineering more immunogenic, yet antigenically faithful, HLA-A*02:01-restricted epitopes. Rational heteroclitic optimization may therefore provide a useful platform for the development of next-generation therapeutic vaccines for sarcoma and other tumors with low intrinsic immunogenicity.
Related
- Human CD4 T cells coordinate antitumor immunity through indirect antigen presentation
- Peptide-Based Nanocomplexes Enable Transferrin-Mediated Uptake and p53-Driven Antitumor Activity in 2D and 3D Glioblastoma Models
- Cytokine-Mediated Plasticity in the Molecular Requirements for Peptide-Loading Complex Formation and Antigen Presentation
- BenchMHC: a reproducible framework for peptide-MHC presentation prediction
- Combinatorial in situ cancer vaccines: unlocking broad and enhanced antitumor responses
BibTeX
@article{mauriello2026peptide,
title = {{Peptide optimization to improve antigen presentation and antitumor responses in sarcoma}},
author = {Angela Mauriello and Concetta Ragone and Beatrice Cavalluzzo and Anna Lucia Tornesello and Ottavia Clemente and Fernanda Picozzi and Michele Gallo and Salvatore Tafuto and Luigi Buonaguro and Maria Tagliamonte},
journal = {Frontiers in immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1960095},
url = {https://europepmc.org/article/PMC/PMC13669185},
note = {CC BY},
}
RIS
TY - JOUR
TI - Peptide optimization to improve antigen presentation and antitumor responses in sarcoma
AU - Angela Mauriello
AU - Concetta Ragone
AU - Beatrice Cavalluzzo
AU - Anna Lucia Tornesello
AU - Ottavia Clemente
AU - Fernanda Picozzi
AU - Michele Gallo
AU - Salvatore Tafuto
AU - Luigi Buonaguro
AU - Maria Tagliamonte
PY - 2026
DA - 2026/10/01
JO - Frontiers in immunology
DO - 10.3389/fimmu.2026.1960095
UR - https://europepmc.org/article/PMC/PMC13669185
AB - Sarcomas are rare and heterogeneous malignancies for which therapeutic options remain limited, particularly in advanced disease. Standard treatments, including surgery, radiotherapy, chemotherapy, and approved targeted agents, provide marginal improvements in progression-free and overall survival, highlighting the need for immunotherapeutic strategies. Therapeutic cancer vaccines represent a promising strategy, but clinical efficacy has been limited by low antigen immunogenicity and an immunosuppressive tumor microenvironment (TME). Enhancing antigen presentation and T-cell receptor (TCR) engagement through heteroclitic peptide engineering may overcome immune tolerance and improve vaccine efficacy. Preliminary data from our group demonstrate that heteroclitic peptides modified at TCR-facing and anchor residues enhance antigen-specific T-cell recognition, cross-reactivity with wild-type epitopes, and tumor control in preclinical models. In this study, we aim to design and validate optimized heteroclitic epitopes derived from sarcoma-associated TAAs. We developed an integrated computational and experimental workflow to identify and optimize HLA-A*02:01-restricted epitopes derived from sarcoma-associated TAAs. Candidate wild-type (WT) peptides were selected using NetMHCpan 4.1 based on predicted HLA binding affinity and subsequently engineered through systematic amino acid substitutions to generate heteroclitic variants. Optimized peptides were evaluated by structural modeling and molecular docking, followed by experimental in vitro validation using T2-cell HLA stabilization assays. Their immunogenicity was assessed ex vivo in peripheral blood mononuclear cells (PBMCs) isolated from HLA-A*02:01-positive sarcoma patients using IFN-γ ELISpot and peptide–HLA dextramer analyses. The sequential optimization strategy generated heteroclitic variants with markedly improved predicted HLA-A*02:01 binding for most target proteins. Structural modeling indicated preservation of the peptide backbone and TCR-accessible surface for the majority of selected variants. These predictions were supported experimentally: several heteroclitic peptides enhanced HLA-A*02:01 stabilization and prolonged peptide–MHC complex persistence in T2 cells. Ex vivo, optimized peptides induced stronger antigen-specific IFN-γ responses than their wild-type counterparts, with significant increases for SET, CAGE, PTPN1 and MAGE-A3, while multimer staining demonstrated recognition of heteroclitic peptide–HLA complexes by wild-type-primed CD8 ⁺ T cells. These findings establish a transferable workflow for engineering more immunogenic, yet antigenically faithful, HLA-A*02:01-restricted epitopes. Rational heteroclitic optimization may therefore provide a useful platform for the development of next-generation therapeutic vaccines for sarcoma and other tumors with low intrinsic immunogenicity.
SN - 1664-3224
ER -